Investment Catalyst Pitching Showcase
The Royal Society of Chemistry, in partnership with the UK Business Angels Association (UKBAA) present to you the 7th edition of the Investment Catalyst.
Our joint aim is to connect the UK’s leading chemistry-focused start-ups and scale-ups with angel and early stage investors through the Royal Society of Chemistry’s vast network of science entrepreneurs and UKBAA’s community of leading investors.
Over the last four years, the Investment Catalyst has presented 47 leading innovators using chemistry to revolutionise life sciences, energy supply, construction, food and drink, the automotive industry and more. We have seen our cohort of businesses raise a total of £3m in funding from attending investors, and we’re thrilled to have seen an incredible exit from one of our finalists at a phenomenal £623m!
This is an investor only event.
The Presenting Businesses:
Chromition’s ‘Digital Histopathology Screening Platform’ (DHSP)’ is transforming the way histopathology is conducted globally. Enabling for the first time the rapid, precise and cost effective diagnosis of cancer in a single tissue biopsy and informing the optimal choice of personalised treatment to reduce the economic cost of cancer to healthcare providers and provide better health outcomes that enhance quality of life.
envoPAP is a vertically-integrated sustainable materials company creating sustainable and commercially viable alternatives to single-use plastics and wood tree-based products using agricultural waste.
FluoretiQ developed the NANOPLEX platform to reduce the time to correctly diagnose bacterial infections from 2 days to 15 minutes. NANOPLEX has a total market potential of £1 Bn spread across infectious disease testing, meat and poultry testing and oncology. FluoretiQ will leverage strategic partnerships to accelerate market access.
Interface Polymers is bringing to market a revolutionary new family of diblock polymers, Polarfin® Products. By using different polyolefin blocks and different polar functionalities, Polarfin® chemistry can be fine-tuned to make chains of variable length which will allow customised solutions for many different applications. Polarfins® will enable the combination of a wide range of currently incompatible plastics to form new polymer alloys which offer unique properties.
What goes in the oceans eventually arrives on our plates. Plastic microbeads used in cosmetics, paints and coating, and many other applications pollute the oceans and are an environmental and health hazard. Naturbeads is scaling up a technology to produce biodegradable cellulose beads to replace polluting plastic microbeads.
NeoGenome creates and licenses genetically-modified organisms (GMOs) for the sustainable production of chemicals at a significantly lower cost than traditional methods. Our technology also helps to reduce landfill waste, to reduce pollution, to produce safer (non-toxic) products and to use resources more efficiently. They do this by using their own novel AI-driven R&D platform.
New Path Molecular Research Ltd
Engineering the chemistry of the next generation of cancer therapy, New Path Molecular is developing IP for license to the pharmaceutical industry. They combine cutting edge chemistry developed by Prof S. V. Ley at the University of Cambridge, lipid biology from the Babraham Institute and pharma industry experience to deliver innovation.
Somnus is end-user led with a team that is deeply rooted in clinical care and research-led innovations. Their technology satisfies an unmet need and their scalable solution will facilitate the safer adoption of intravenous anaesthesia throughout the world. Thus allowing more patients to benefit from superior propofol-based anaesthesia instead of gases.
